// Account brief

MSD

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. Covers Merck & Co., known as MSD outside the US and Canada. It is a separate company from Merck KGaA, Darmstadt, Germany.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 5 4 live 4 3
Research labs and data 1 2 funded or contracted 0 2

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

MSD scores 5 out of 10 for priority and 4 out of 10 for delivery in AI in drug discovery. It describes two foundation models it developed, including KERMT, built with NVIDIA and released as open source, with no adoption metric published. Research labs and data scores 1 for priority and 2 for delivery: a multi-year agentic AI platform investment with Google Cloud, valued at up to $1 billion, is to deploy Gemini Enterprise across R&D workflows, but it is funded rather than shown running. In the last 12 months four AI discovery commitments were made public, with Protillion, Infinimmune, Mayo Clinic Platform and Illumina's Billion Cell Atlas, against two the year before; the only research labs and data commitment, a Benchling collaboration for regulated bioanalytical workflows, came the year before. On 6 October 2026 MSD had 3 AI in drug discovery roles and 2 research labs and data roles open, and the AI postings ask for experience with tools such as Databricks, MLflow, PyTorch and Claude Code.

AI in drug discovery

What the company says: Priority 5

The collaboration builds on Merck's broader investments in AI/ML-enabled discovery, spanning computational or spatial biology, AI foundation models and real-world data

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026

Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisions

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026

We also use data science, AI, and machine learning ... (ML) to help overcome bottlenecks in discovery, research, and development.

Purpose for Progress Impact Report 2025/2026, 18 Aug 2026, p. 22

We're also taking important additional steps to accelerate our ongoing transformation as it relates to Artificial ... Intelligence ... create a real opportunity to advance the innovation in our pipeline

Q1 2026 Earnings Prepared Remarks, 30 Apr 2026, p. 5

Drive innovation and ... productivity enabled ... by digital and data

Purpose for Progress Impact Report 2025/2026, 18 Aug 2026, p. 8

What it shows running: Delivery 4, live

KERMT isn't just helping our researchers; as an open-source model, its code is available to the whole scientific community.

Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026

We recently developed two foundation models which uncover patterns in disease to find better drug targets, allow faster molecular design and rapidly test small molecules

5 ways we're transforming artificial intelligence into impact (story), 9 Jan 2026

Developed in collaboration with Nvidia, KERMT, pronounced "Kermit" and short for Kinetic GROVER Multi-Task, is a deep-learning computer model trained on more than 11 million molecules.

Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026

today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026

"AI is sometimes cutting timelines by 30% or more, improving drug candidate quality and reducing costs," Cheng said.

Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026

where we have seen meaningful benefits it's, frankly, when we talk about the fact that we're seeing above average PTRS ... a lot of that is driven by what we have been able to already do with AI

Merck & Co Inc at Morgan Stanley Global Healthcare Conference - edited transcript, 14 Sep 2026, p. 12

And we actually are ... benefiting from that and actually are building those savings into our budgets today.

Merck & Co Inc at Morgan Stanley Global Healthcare Conference - edited transcript, 14 Sep 2026, p. 12

Commitments made public in the last 12 months: 4

Commitments made public in the year before: 2

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Asked for as experience: Amazon Web Services (AWS), Claude Code, Databricks, Docker, GitHub Actions, Google Cloud Platform (GCP), MLflow, Python, PyTorch.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Research labs and data

What the company says: Priority 1

This includes deploying Gemini Enterprise across end-to-end R&D workflows

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026

What it shows running: Delivery 2, funded or contracted

This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck's research & development (R&D), manufacturing, commercial, and corporate functions

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026

This includes deploying Gemini Enterprise across end-to-end R&D workflows

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 1

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 2

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: Jira.

Asked for as experience: Amazon Web Services (AWS).

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Who decides on new lab automation and scientific data systems across Global Research IT, the regulated bioanalytical team that uses Benchling and the enterprise Google Cloud agentic programme, now under a Chief Information and Digital Officer appointed to take up the role on 1 September 2026?
  2. Who decides whether MSD licenses an external AI discovery platform, as with Variational AI, Infinimmune and Protillion, or builds its own foundation models, and do such deals run through business development and licensing, procurement or the research functions?

Coverage limits

Business Wire, GlobeNewswire, sec.gov, Fierce Pharma, the IHI site, msdcareers.com and several trade sites blocked access, so partner releases were read through BioSpace and 1stOncology copies and the 10-K filings through company-hosted copies. The search budget ran out, so several checks did not run, including UK Biobank and AISB membership, the NVIDIA newsroom and the MSD Global Health Innovation Fund portfolio. A late top-up search found the Benchling collaboration that the main searches had missed, which shows other items may also be missing. Three results that may concern Merck KGaA, a separate company, could not be read and are not used.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call